What do you make of the fact that only roughly 15-20% of expenditures is research and development in pharmaceutical industry? How does changing IP affect this number?
Why do you think companies like GlaxoSmithKline would change the image of depression in Japan? Are the companies acting more out of their self interest or are they more focused on solving global health issues/stigmas?
What are the implications of limiting/altering current IP legislation as it relates to pharmaceutical industry? How would this affect R&D?
No comments:
Post a Comment